Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

4

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adenosine A2a receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cancer

1

Parkinson's disease

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Vernalis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

ECHA (EC/EINECS)

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

4

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

VIPADENANT

LDR3USH1NJ

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Adenosine A2a receptor

Conditions:

Parkinson's disease

Vipadenant (V2006) is a small molecule, adenosine A2A receptor antagonist that was being investigated in Parkinson's disease. Due to safety concerns development ceased in 2010 and the rights were regained from Biogen Idec in 2011 with no further inve...

stment made. In October 2014, RedoxTherapies licensed Vipadenant as it has the potential to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.

PHENACYL BROMIDE

754Y0U325I

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

5-TOLYLTRIAZOLE

O9DI72TU6U

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

7-METHYLINDOLE

7Z1E6HIT9S

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

SODIUM 5-TOLYLTRIAZOLE

Q03K5OIJ3A

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1